Menactra meningococcal polysaccharide vaccine
Meningococcal vaccine is a vaccine used against Neisseria meningitidis, a bacterium that causes meningitis, meningococcemia, septicemia, and rarely carditis, septic arthritis, or pneumonia. Mencevax (GlaxoSmithKline) and NmVac4-A/C/Y/W-135 (JN-International Medical Corporation) are used worldwide, but have not been licensed in the United States.
The first meningococcal conjugate vaccine (MCV4), Menactra, was licensed in the U.S. in 2005 by Sanofi Pasteur; Menveo, was licensed in 2010 by Novartis. Both MCV4 vaccines have been approved by the Food and Drug Administration (FDA) for people 2 through 55 years of age. In April 2011, Menactra received FDA approval for use in children as young as 9 months, although the Centers for Disease Control and Prevention (CDC) has not made recommendations for or against its use in children less than 2 years.

Price:
Price 2000 INR / Box
Minimum Order Quantity : as per requirement , , Box
Feature : Other , Vial, Sterile, Preservative free
Use : Other Uses, Hospital, Clinic, Personal
Shelf Life : 2 Years
Treatments & Functions : Other, AntiCancer, Antineoplastic
Price 425 INR / Piece
Minimum Order Quantity : as per requirement Piece
Feature : Other , Sterile, Singleuse Syringe
Use : Other Uses, Clinical, Hospital, Personal
Shelf Life : 24 Months
Treatments & Functions : Other, Used to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy
Minimum Order Quantity : 100 Bottles
Feature : Other
Use : Body
Shelf Life : 12 Hours
Treatments & Functions : Other
Feature : PainReducers
Use : Other Uses, Administered via intravenous infusion as directed by a medical professional
Shelf Life : Refer to the packaging for exact expiration date; typically stable for 2 years if stored properly
Treatments & Functions : Other, Used to treat autoimmune conditions such as rheumatoid arthritis Crohns disease and ulcerative colitis by reducing inflammation